0001209191-22-040255.txt : 20220701 0001209191-22-040255.hdr.sgml : 20220701 20220701163701 ACCESSION NUMBER: 0001209191-22-040255 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220701 FILED AS OF DATE: 20220701 DATE AS OF CHANGE: 20220701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Collard Craig A CENTRAL INDEX KEY: 0001363558 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37490 FILM NUMBER: 221061975 BUSINESS ADDRESS: BUSINESS PHONE: 919-678-6611 MAIL ADDRESS: STREET 1: C/O CORNERSTONE THERAPEUTICS INC. STREET 2: 1255 CRESCENT GREEN DRIVE, SUITE 250 CITY: CARY STATE: NC ZIP: 27518 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sierra Oncology, Inc. CENTRAL INDEX KEY: 0001290149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: (605) 376-8679 MAIL ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: ProNAi Therapeutics Inc DATE OF NAME CHANGE: 20040513 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-01 1 0001290149 Sierra Oncology, Inc. SRRA 0001363558 Collard Craig A C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DR., SUITE 110 SAN MATEO CA 94404 1 0 0 0 Common Stock 2022-07-01 4 D 0 13500 55.00 D 0 D Stock Option (right to buy) 13.88 2022-07-01 4 D 0 10000 0.00 D 2030-05-28 Common Stock 10000 0 D Stock Option (right to buy) 18.11 2022-07-01 4 D 0 6000 0.00 D 2031-06-08 Common Stock 6000 0 D The option fully vested on May 28, 2021. Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. The option fully vested on June 8, 2022. /s/ Craig A. Collard; By: Mary Christina Thomson, Attorney-In-Fact 2022-07-01